## **Adults with Congenital Heart Disease:**

## **Happy-end or growing problems?**



#### Jana Rubáčková Popelová

**Center for Adults with Congenital Heart Disease** 

Cardiac Surgery, Na Homolce Hospital, Prague 5

Prague Symposium on CHD, 5.11.2022

206 Detum narozoni Paciest Pohlast/VySka/Hosp	14.08.1974 (48 Rphy) 54.09.1974 (48 Rphy) 54.09.1974 (49 Rphy)	Zamam zi 15.09.2022 07:00:15	(ELA wastrad 6.6 a. Potitisika Skeda V. Konverse J. 293 01 Miadá Boleslav Zarramma Vyhodiseti
14444	mm	www.A	MMMMM
"WWW	www	www.»/	mmmmm
•• WWW	www	WWW vo hr	mannan
WR ANAAA	Annana	mm. m	mmmmm
manna	nannan	nnnn »W	wwwwwwwww
	www	· · · · · · · · · · · · · · · · · · ·	wwwwwwwww











#### **Center for Adults with Congenital Heart Disease**

#### Na Homolce Hospital, Prague

- Since the year 2005
- Adult patients not only from Children Heart Center, but also from cardiologists and hospitals from the whole Czech Republic
- Database: 3759 adult patients with CHD
- Mean age 47 ± 15 years
- New patients 80-100 per year





#### Increasing number of adults with CHD







# Survival and mortality



## How many children with CHD reach adulthood?

7,5 %

(Moons 2010)

- 1956 1980:
   67 %

   1980 1990:
   77 %

   nowadays:
   > 90 % (Moons 2010; Stout 2018)
- Children with simple CHD: 98 %
- Moderately complex CHD: 90 %
- Very complex CHD: 56,4 %
- Univentricular heart: 49 %
- Hypoplastic left heart

1-year mortality in ACHD: 0,9%

Diller 2015; Engelings 2016; Greutmann 2014)



## 5-year mortality of adults with CHD



**EHS: Euro Heart Survey on ACHD** / GUCH 2003-2004, retrospective study, 5-years mortality **Our center**: databasis of adults with CHD, Center in Hospital Na Homolce, 5-years mortality



## Cardiac and non-cardiac mortality of adults with CHD



Diller, Circulation 2015



## Risk stratification and mortality prediction by NT-proBNP in adults with stable CHD



Popelová, Am J Card, 2015



### **Cause of death of adults with CHD**

Heart failure	42 %
Sudden death, arrhythmias	23 %
Pneumonia	10 %

- Tumor6 %Bleeding5 %
- Perioperative death 13 16 %

Diller 2015; Engelings 2016; Greutmann 2014)



## Heart failure in ACHD



European Heart Journal (2016) **37**, 1419–1427 doi:10.1093/eurheartj/ehv741 **CURRENT OPINION** 

Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology

Werner Budts<sup>1\*</sup>, Jolien Roos-Hesselink<sup>2</sup>, Tanja Rädle-Hurst<sup>3</sup>, Andreas Eicken<sup>4</sup>, Theresa A. McDonagh<sup>5</sup>, Ekaterini Lambrinou<sup>6</sup>, Maria G. Crespo-Leiro<sup>7</sup>, Fiona Walker<sup>8</sup>, and Alexandra A. Frogoudaki<sup>9</sup>

<sup>1</sup>Congenital and Structural Cardiology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium; <sup>2</sup>Department of Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands; <sup>3</sup>Department of Pediatric Cardiology, Saarland University Medical Center, Homburg, Germany; <sup>4</sup>Deutsches Herzzentrum München, Munich, Germany; <sup>5</sup>Deutsches Viewer Cardiology, Cardiology, Saarland University Medical Center, Homburg, Germany; <sup>4</sup>Deutsches Herzzentrum München, Munich, Germany;

## Heart failure in ACHD

#### **Systemic RV:**

- Pharmacological options are not well defined
- The effect of ACEI/ARB is questionable
- Valsartan did not improve survival, had less events in symptomatic pts, 88 pts (van Dissel, 2018)
- no evidence of ACEi/ ARB benefit on morbidity and mortality, 359 pts. (Ladouceur, Heart, 2021)
- ARNI? Sacubitril/valsartan 20 pts., well tolerated, decrease of NT-proBNP
- SGLT2i ??

#### LV systolic dysfunction

- Treatment of HF as in non-CHD (BB, ACEI/ARB, ARNI, MRA, SGLTi??),
- Diuretics, some pts have Digoxin since childhood
- CRT

#### **RV systolic dysfunction**

Diuretics, pulmonary vasodilatation in PH

#### **Fontan circulation**

Decrease of PAP, diuretics, MRA, pulmonary vasodilatation

#### Diastolic heart failure in CHD !!!







# Systemic right ventricular dysfunction after operation for systemic tricuspid regurgitation

#### d-TGA, Mustard correction, mechanical AV valve



#### CCTGA after repair of systemic tricuspid valve





#### Left ventricular dysfunction



AVSD with late mitral valve replacement due to severe MR mechanical valve, both mitral leaflets and chordae were removed





# Arrhythmias in ACHD

ESC GUIDELINES

#### 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC)

Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC)

European Heart Journal (2022) 43, 3997-4126

propean Society https://doi.org/10.1093/eurhearti/ehac262

ESC

Authors/Task Force Members: Katja Zeppenfeld<sup>\*†</sup> (Chairperson) (Netherlands), Jacob Tfelt-Hansen <sup>\*†</sup> (Chairperson) (Denmark), Marta de Riva<sup>\*\*</sup> (Task Force Coordinator) (Netherlands), Bo Gregers Winkel<sup>\*\*</sup> (Task Force Coordinator) (Denmark), Elijah R. Behr (United Kingdom), Nico A. Blom<sup>1</sup> (Netherlands), Philippe Charron (France). Domenico Corrado (Italv). Nikolaos Dagres Circulation: Arrhythmia and Electrophysiology

2022

#### **AHA SCIENTIFIC STATEMENT**

Arrhythmias in Repaired Tetralogy of Fallot: A Scientific Statement From the American Heart Association

Eric V. Krieger, MD, Chair; Katja Zeppenfeld, MD, PhD, Vice Chair; Elizabeth S. DeWitt, MD; Valeria E. Duarte, MD; Alexander C. Egbe, MD; Christiane Haeffele, MD; Kimberly Y. Lin, MD, FAHA; Melissa R. Robinson, MD; Christy Sillman, NP; Shailendra Upadhyay, MD; on behalf of the American Heart Association Adults With Congenital Heart Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young and Council on Clinical Cardiology

#### Risk estimates for arrhythmic events and bradycardias in ACHD

	Supraventricular arrhythmias		Ventricular arrythmias and SCD		Bradycardia				
	pe of CHD AVRT LART/ AF Sustained SC	5CD	SN	SND		AV block			
Type of CHD		EAT	AF	AF VT	SCD	Congenital	Acquired	Congenital	Acquired
Secundum ASD		++	++			(+)	+		(+)
Superior sinus venosus defect		++	+				+		
AVSD/primum ASD		++	++	(+)		(+)		(+)	++
VSD		+	(+)	+	(+)*				+
Ebstein anomaly	+++	++	+	(+)	++b		++		
TOF		++	++	++	++		+		+
TGA									
Atrial switch		+++	+	++c	+++b		+++		+
Arterial switch		+		+¢	(+)		(+)		
ccTGA	++	+	+	(+)	++6			+	++
Fontan operation									
Atriopulmonary connection		+++	++		+5		++		
Intracardiac lateral tunnel		++	+		+>		++		
Extracardiac conduit		+	+		+6		+		
Eisenmenger physiology Incompletely palliated CHD		++	++		++4				

Empty cells indicate that although not specifically indicated, arrhythmic events may occur (no symbol).

= mild risk



al risk 🚽

++ = moderate risk

+++ = high risk



European Society of Cardiology doi:10.1093/eurheartj/ehaa554 **ESC GUIDELINE** 

## 2020 ESC Guidelines for the management of adult congenital heart disease

The Task Force for the management of adult congenital heart disease of the European Society of Cardiology (ESC)

Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Adult Congenital Heart Disease (ISACHD)

Authors/Task Force Members: Helmut Baumgartner\* (Chairperson) (Germany),

## Antiarrhythmic transcatheter interventions in adults with CHD

## in Na Homolce Hospital

• 182 transcatheter ablations in ACHD

MUDr. Jan Škoda, MUDr. Petrů, prof. Neužil

- 50 high complexity ablations
- 39 with limited venous approach: 27x retrograde transaortic approach with remote magnetic navigation



9x baffle punction 1x transhepatic approach in IVC agenesis + BCPA 2x azygos vein

EA mapping with CT integration, focal atrial tachycardia, from right paraseptal region d-TGA, SV, TCPC, transaortic approach with remote magnetic navigation

#### Monomorphic ventricular tachycardia

#### in repaired TOF

- 36-years old lady with repaired TOF 32 years ago
- No symptoms, NYHA I,
- ECG: RBBB with QRS 160 msec
- After physical effort she had syncope and resuscitation, on ECG sustained monomorphic ventricular tachycardia with 300 beats per minute
- After electric cardioversion sinus rhythm 66/min, RBBB
- Echocardiography: mild RV dilatation, good RV systolic function.
- Severe pulmonary regurgitation
- According to the Guidelines she had no indication for pulmonary valve replacement.



## **IART in repaired Tetralogy of Fallot**





- 48-years old man with repaired TOF
- Good function of pulmonary bioprosthesis
- Syncope when going on the bicycle
- ECG: Postincisional flutter with rapid ventricular response (200 beats per minute (1:1 conduction),
- Electrical cardioversion
- Transcatheter ablation is planned soon

## Operations and interventions in adulthood

## Our experience with surgery of adults with CHD



- Surgery was performed in 1245 adult patients with CHD (up to 30.6.2022)
- Average age at surgery 40 ± 14 years (16 79 years)
- History of previous operation: 46 % (573) of our operated patients
- History of previous 3-6 operations: 16 % (202 pts)
- Most reoperations: truncus arteriosus and pulmonary atresia



Photo: MUDr. Štěpán Černý





#### Our experience with surgery of adults with CHD

30-days mortality:1in-hospital mortality:7

## 1,3 % 1,7 %

#### In-hospital mortality:

- Pulmonary atresia
- Ebstein anomaly
- COA: 0%
- TOF after radical repair:
- Pulmonary stenosis:
- Truncus arteriosus:

- **7%** (+2/28; sepsis, IE) **4,5%** (+4/87)
  - % (+0/42)
- **0 %** (+0/156)
- stenosis: **0 %** (+0/70)
  - **0 %** (+0/9) (one death on WL OTS)

#### **Our surgeons:**

MUDr. Roman Gebauer MUDr. Štěpán Černý MUDr. Petr Pavel MUDr. Ivo Skalský MUDr. Aleš Klváček



#### Risk factors of mortality after operation of adults with CHD

- permanent cyanosis before surgery (OR 60,5), in-hospital mortality 41% (+7/17)
- NYHA class III-IV (OR 30,8), in-hospital mortalty **12%** (+ 22/170)

Tabulka 4 – Rizikové faktory časných i pozdních úmrtí po operaci vrozené srdeční vady v dospělosti					
Rizikový faktor	Přeživší (N = 780)	Zemřelí (N = 25)	р	OR	
NYHA třída III–IV před operací	150 (19 %)	22 (88 %)	< 0,0001	30,8	
Cyanóza před operací	6 (0,77 %)	8 (32 %)	< 0,0001	60,5	
Anamnéza městnavého srdečního selhání	35 (4,5 %)	6 (24 %)	0,001	6,7	
Přítomnost mechanické chlopenní náhrady	120 (15,4 %)	10 (40 %)	0,0032	3,7	
Univentrikulární cirkulace	19 (2,4 %)	3 (12 %)	0,0276	5,4	
Plicní hypertenze	106 (13,6 %)	7 (28 %)	0,072	2,4	
Arytmie	238 (30 %)	12 (48 %)	0,078	2,1	
Muži	419 (54 %)	9 (36 %)	0,103	0,48	
Věk v době operace	39	40	0,636	NA	
Počet předchozích operací Předchozí operace na pacienta	538 0,63	35 1,4	0,00033	NA	

NA – nelze určit, OR – odds ratio.

#### (Rubáčková Popelová, Cor Vasa, 2016)





#### **Operations of systemic right ventricle**

N = 26 operations; 2,3% of all CHD operations, in-hospital mortality 7,6%



#### CCTGA, systemic RV is left-side

CCTGA: 15 operations, **mortality 13%** (+2/15)

#### **Operations – systemic tricuspid valve:**

12x mechanical prosthesis2x bioprosthesis6x tricuspid valve repair

#### **Aortic valve:**

1x bioprosthesis

#### **Resynchronisation therapy in TGA/Must/Senn**

5x epicardial electrodes implantation 1x extraction of epicardial electrodes due to infection



TGA, Mustard, Senning, systemic RV is right-side

TGA after atrial switch: 11 reoperations, **mortality 0%** (0/11)

#### **Operations of adults with univentricular circulation**

N = 36 operations; 3% of all CHD operations, 47% of all our 76 followed-up Fontans

in-hospital mortality: 16,7% (+6/36)

- Types of operations:
- TCPC in adulthood, Kawashima (6x)
- conversion of classical Fontan operation to TCPC (4x)
- mitral valve repair (5x)
- closure of tricuspid valve (4x)
- mechanical prosthesis (5x)
- excision of ventricular septum to remove of subaortic stenosis (2x)
- repair of pulmonary veins stenosis (1x)
- excision of mediastinal tumor (1x)
- completion of TCPC by hepatic veins connection (3x)
- epicardial electrodes (5x)

Intra-atrial lateral tunnel with fenestration

extracardial conduit

Stenosis of left-sided pulmonary veins after RFA









#### **Tetralogy of Fallot**

N = **156** operations; **13%** of all CHD operations

mortality **0 %** (+0/156)







#### **Reoperations TOF, DORV, PA and other complex CHD:**

193 pulmonary bioprosthesis
60 pulmonary homografts
17 mechanical pulmonary prosthesis
8 pulmonary repair and Ozaki autopericardial valve

**42 TPVI:** transcatheter pulmonary valve implantation in homograft or bioprosthesis





TPVI Melody

**TPVI Edwards Sapien** 

#### **Ebstein anomaly of tricuspid valve**



(N = 87 operations; 7 % of all CHD operations, in-hospital mortality 4,5% (+4/87), daSilva mortality 0%



Ebstein anomaly of tricuspid valve

Our oldest operated patient with Ebstein anomaly: In 68 years: tricuspid bioprosthesis In 72 years: TS (15/6mmHg) a TR, valve-in-valve implantation





Cone-repair (daSilva)

In our center: since 2010 Operations performed by Roman Gebauer, MD





## Infective endocarditis

## IE in adults with CHD in our registry

- BAV 9,5 % (60/627)
- VSD 5% (33/660)
- ASD 2% (16/804)
- IE on pulmonary valve:
- PVR HMGR: 22% (23/106) HMGR, also from childhood
- PVR bio: **12 %** (25/208)
- PVR mech: **16,7%** (3/18)
- TPVI: **12%** (5/42 all TPVI)
- TPVI Melody 26 % (5/19 TPVI Melody only)



Unoperated BAV with IE, abscess emptying to LVOT, AS, AR, severe dilatation of aortic root,



## Staphylococcus IE on older pulmonary HMGR with severe pulmonary stenosis





Grad. 89mmHg









Out of 1293 women with CHD in our database 389 were pregnant during our follow-up = 30 %



**ESC GUIDELINES** 

## 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy

The Task Force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)

Endorsed by: the International Society of Gender Medicine (IGM), the German Institute of Gender in Medicine (DGesGM), the European Society of Anaesthesiology (ESA), and the European Society of Gynecology (ESG)

Authors/Task Force Members: Vera Regitz-Zagrosek\* (Chairperson) (Germany), Jolien W. Roos-Hesselink\* (Co-Chairperson) (The Netherlands), Johann Bauersachs

#### Fontan circulation and pregnancy – difficult decision

- Pregnancy with high risk is possible only in the "best" Fontans,
- NYHA I, no residual findings, VO2max ≥ 25 ml/kg/min
- 50 % abortions, preliminary delivery and neonatal death, frequent infertility



Fontan – Doty

**TCPC** 

Our experience: 34 women with Fontan circulation in fertile age
 13x pregnancies in 9 women (26 %), 1 death after delivery
 7x healthy children (= 54 %)
 6x spontaneous abortion



# Quality of life

## Quality of life in patients with TCPC and healthy population



### SF-36 questionnary



Popelová, Cor Vasa, 2018

#### The role of employment for unrepaired and repaired complex cyanotic CHD





Patients with unrepaired cyanotic CHD without employment had the highest depression score Also patients with repaired cyanotic CHD, (but not the controls) had higher depression score if unemployed.

#### **Quality of life in repaired complex cyanotic CHD**



#### 223 adults with repaired complex cyanotic CHD

mean age 36 ± 10 years

Diagnoses: PA, TGA, TOF, SV (TCPC)

- 57 % had higher education (secondary school or university)
- 46 % had full-time job
- 96 % were in NYHA class 1 or 2
- 40 % had regular physical activity including recreational sports
- **31** % women delivered a baby (39/95)

### Do adults with CHD represent happy- end or growing problems.....??





Lady with Ebstein anomaly type C, born in 1946, operated in 68 yrs



Lady with TCPC



Lady with truncus arteriosus and

6 cardiac operations

Lady with TOF after reoperation









.... adults with CHD represent growing success....

..... based on the excellent results of Childern's Heart Center together with

the effort of the Centers for adults and their co-operation....

## Congratulations to 45 birthday !!!!





### A lot of success !!!

Many thanks for the excellently operated patiens, for the co-operation and friendship....



## Longitudinal follow-up with repeated NT-proBNP measurments

NT-proBNP	Number of pts with at least one sample exceeding this value	mortality
<b>220 pg/ml</b> (median of all patients)	388 pts with at least one NT-proBNP value ≤ 220 pg/ml	1 %
<b>1548 pg/ml</b> (median of deceased patients)	54 pts with at least one NT-proBNP value > 1548 pg/mD	41 %

Popelová, Am J Card, 2015